A cost-effectiveness analysis of amivantamab plus lazertinib versus osimertinib in the treatment of US and Chinese patients with EGFR-mutated advanced non-small cell lung cancer.

Abstract excerpt

BACKGROUND: The combination of amivantamab and lazertinib (AL) has demonstrated clinically significant efficacy in patients with previously untreated EGFR-mutated advanced non-small cell lung cancer (NSCLC). However, its economic value relative to the standard therapy, osimertinib, remains unclear. This study evaluates the cost-effectiveness of AL regimen compared with osimertinib in US and Chinese healthcare...

Topics

• Humans
• Carcinoma, Non-Small-Cell Lung
• Aniline Compounds
• Lung Neoplasms
• Cost-Benefit Analysis
• ErbB Receptors